Xarelto was first introduced in 2011 as part of a new class of medications that have been aggressively promoted as superior to Warfarin (Coumadin), because it is easier to use and requires less frequent monitoring.
In April 2011, a study of more than 8,000 people compared Xarelto to Lovenox in patients hospitalized for acute medical conditions, such as heart failure, infectious disease, and breathing difficulty.
Patients taking Xarelto had significantly higher rates of bleeding — they were more than twice as likely to experience bleeding compared to Lovenox. 4.1% of patients taking Xarelto experienced bleeding, compared to 1.7% taking Lovenox.
If you or a loved one used Xarelto and experienced:
You may be entitled to significant compensation from the manufacturer.
There are time deadlines to file a claim so don’t wait – act now.
Free Xarelto Legal Consultation
Thank you for submitting your information.